Zanzalintinib for Metastatic Clear Cell Kidney Cancer with Bone Metastases
This study is testing a drug called zanzalintinib along with a bone-strengthening agent for people with clear cell kidney cancer that has spread to the bones. You might be able to join if your cancer has spread and has already been treated with 1 to 3 other therapies, including at least one immune-based treatment. The main goal is to see what percentage of participants do not have their cancer grow or spread after 12 months. The study is currently recruiting 20 participants, but its overall status is unclear.
- Study design
- This is a single-institution, phase 2 study involving 20 participants. It is testing zanzalintinib plus an investigator-chosen bone strengthening agent.
- What's involved
- You would receive zanzalintinib by mouth and a bone strengthening agent through an IV. You would also undergo bone scans and CT scans.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main goal looks at how long you go without your cancer growing or spreading, up to 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
At a glance
Conditions
NCT07043608
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of California, San Francisco
San Francisco, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Kelly Fitzgerald, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Proportion of participants who have not progressed at 12 months (PFS12)Up to 12 months
The proportion of participants who have not demonstrated radiographic progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or demonstrated clinical progression-free survival (PFS) at 12 months after the start of study treatment. Twelve-month landmark PFS rate will be obtained with 95% confidence interval using the Kaplan-Meier method.